Sentinel Initiative's Potential Shortcomings Illuminated At Avandia Panel

The recent Avandia safety panel meeting - during which two FDA advisory committees were unswayed by the results of an observational study by one of the agency's own scientists - underscores the challenges that FDA's Sentinel Initiative will have in becoming an essential regulatory tool

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet